Evidence map›Paper›PMID 36430531›Full record

ArticleInternational journal of molecular sciences2022

The Protective Effect of Zebularine, an Inhibitor of DNA Methyltransferase, on Renal Tubulointerstitial Inflammation and Fibrosis.

Eun Sil Koh, Soojeong Kim, Mina Son, Ji-Young Park, Jaehyuk Pyo, Wan-Young Kim, Minyoung Kim, Sungjin Chung, Cheol Whee Park, Ho-Shik Kim and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  6. Sex-specific epigenetic programming in renal fibrosis and inflammation.American journal of physiology. Renal physiology · 2023
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Eun Sil KohDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0003-1282-7876
Soojeong KimDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Mina SonDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Ji-Young ParkDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Jaehyuk PyoDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Wan-Young KimDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Minyoung KimDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Sungjin ChungDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.ORCID 0000-0002-9886-8339
Cheol Whee ParkDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Ho-Shik KimDepartment of Biochemistry, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Seok Joon ShinDepartment of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Catholic University of Korea · KRThe Catholic University of Korea Incheon St. Mary's Hospital · KR

Funding

National Research Foundation of Korea 2019R1A5A2027588National Research Foundation of Korea NRF-2017R1D1A1B03031133National Research Foundation of Korea NRF-2017R1D1A1B03035813
6 · The paper itself

Abstract

Renal fibrosis, the final pathway of chronic kidney disease, is caused by genetic and epigenetic mechanisms. Although DNA methylation has drawn attention as a developing mechanism of renal fibrosis, its contribution to renal fibrosis has not been clarified. To address this issue, the effect of zebularine, a DNA methyltransferase inhibitor, on renal inflammation and fibrosis in the murine unilateral ureteral obstruction (UUO) model was analyzed. Zebularine significantly attenuated renal tubulointerstitial fibrosis and inflammation. Zebularine decreased trichrome, α-smooth muscle actin, collagen IV, and transforming growth factor-β1 staining by 56.2%. 21.3%, 30.3%, and 29.9%, respectively, at 3 days, and by 54.6%, 41.9%, 45.9%, and 61.7%, respectively, at 7 days after UUO. Zebularine downregulated mRNA expression levels of matrix metalloproteinase (MMP)-2, MMP-9, fibronectin, and Snail1 by 48.6%. 71.4%, 31.8%, and 42.4%, respectively, at 7 days after UUO. Zebularine also suppressed the activation of nuclear factor-κB (NF-κB) and the expression of pro-inflammatory cytokines, including tumor necrosis factor-α, interleukin (IL)-1β, and IL-6, by 69.8%, 74.9%, and 69.6%, respectively, in obstructed kidneys. Furthermore, inhibiting DNA methyltransferase buttressed the nuclear expression of nuclear factor (erythroid-derived 2)-like factor 2, which upregulated downstream effectors such as catalase (1.838-fold increase at 7 days, p < 0.01), superoxide dismutase 1 (1.494-fold increase at 7 days, p < 0.05), and NAD(P)H: quinone oxidoreduate-1 (1.376-fold increase at 7 days, p < 0.05) in obstructed kidneys. Collectively, these findings suggest that inhibiting DNA methylation restores the disrupted balance between pro-inflammatory and anti-inflammatory pathways to alleviate renal inflammation and fibrosis. Therefore, these results highlight the possibility of DNA methyltransferases as therapeutic targets for treating renal inflammation and fibrosis.

Indexed as

NephritisRenal Insufficiency, ChronicUreteral ObstructionAnimalsCytidineDNADNA Modification MethylasesFibrosisInflammationMiceCytidineDNADNA Modification Methylasespyrimidin-2-one beta-ribofuranosideDNA methyltransferasefibrosisinflammationoxidative stressunilateral ureteral obstruction

Identifiers

PMID36430531
PMCPMC9697081
OpenAlexW4309210951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.